Washington, D.C. 20549
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02
|
Results of Operations and Financial Condition
|
On May 22, 2017, Alere Inc. (the “Company” or “Alere”) issued a press release announcing certain preliminary unaudited financial results for the fiscal year ended December 31, 2016 and certain preliminary and unaudited financial information for the quarter ended March 31, 2017. The Company also provided an update on its Annual Report on Form 10-K for the fiscal year ended December 31, 2016. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The financial results presented in the press release are preliminary and may change. These preliminary results include calculations that have been prepared by Alere management and have not been reviewed or audited by our independent registered public accounting firm. There can be no assurance that Alere’s actual financial results will not materially differ from the preliminary unaudited financial data presented in the press release. Actual results may differ for a number of reasons, including the impact of any changes that may be required as a result of the ongoing review by Alere of revenue recognition and other adjustments that may be made in connection with the finalization of the fiscal year 2016 financial statements and the finalization of the financial statements for the three months ended March 31, 2017 (which may also impact the financial results for any other period presented therein). In addition, the preliminary unaudited financial data presented for the periods ended December 31, 2016 and March 31, 2017 should not be viewed as a substitute for the full financial information prepared in accordance with U.S. generally accepted accounting principles, including footnotes, which is expected to be filed with the Securities and Exchange Commission as soon as practicable. Please see the “2016 Form 10-K Update” and “Cautionary Statement Regarding Forward-Looking Statements” sections of the press release for further information.
The information provided under this Form 8-K (including Exhibit 99.1) is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Cautionary Statement Regarding Forward Looking Statements
This communication contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as
“preliminary”, “may,” “could,” “should,” “would,”
“intend,” “will,” “expect,” “anticipate,” “believe,”
“estimate,” “can”, “continue” or similar words. A number of important factors could cause
actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott
Laboratories (“Abbott”) may not be completed in a timely manner or at all; (ii) the failure to receive, on a
timely basis or otherwise, the required approval of the proposed merger with Abbott by Alere’s stockholders, (iii) the
possibility that competing offers or acquisition proposals for Alere will be made; (iv) the possibility that any or all of
the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any
required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions
placed on such approvals); (v) the occurrence of any event, change or other circumstance that could give rise to the
termination of the Agreement and Plan of Merger, as amended (the “Merger Agreement”) among Alere and Abbott
pursuant to which Abbott will acquire Alere, including in circumstances which would require Alere to pay a termination fee or
other expenses; (vi) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on
Alere’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers
and others with whom it does business, or its operating results and business generally; (vii) risks related to diverting
management’s attention from Alere’s ongoing business operations; (viii) the risk that stockholder litigation in
connection
with the transactions contemplated by the Merger
Agreement may result in significant costs of defense, indemnification and liability, (ix) the risk that the previously
announced review of certain aspects of revenue recognition is not completed in a timely manner or the scope of such review
expands, (x) the risk that the failure by Alere to file its Form 10-K for the fiscal year ended December 31, 2016 and Form
10-Q for the fiscal quarter ended in March 31, 2017 in a timely manner could lead to the acceleration of the maturity of
certain of Alere’s indebtedness, (xi) the possibility that the previously announced review of certain aspects of
revenue recognition uncovers an additional error or errors in revenue recognition or other financial information which
require additional adjustment which may be material, or material weaknesses in the Company’s internal controls over
financial reporting, (xii) the risk that the Company experiences an acceleration of amounts due under its senior secured
credit facility due to the restatement, any circumstances described in Alere’s Current Report on Form 8-K as filed on
April 17, 2017, this Current Report on Form 8-K or the failure to timely file the Annual Report on Form 10-K for 2016 and
Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2017 (or that the Company could be required to obtain a
waiver under such credit agreement), (xiii) risks relating to the ongoing investigations by the United States Securities and
Exchange Commission (the “SEC”) and the United States Department of Justice, (xiv) the risk that these or other
risk factors impact the expected timing of the filing of the Form 10-K for the fiscal year ended December 31, 2016 and Form
10-Q for the fiscal quarter ended in March 31, 2017, and (xv) the risk factors detailed in Part I, Item 1A, “Risk
Factors,” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (as filed with the SEC on
August 8, 2016) and other risk factors identified herein or from time to time in our periodic filings with the SEC. Readers
should carefully review these risk factors, and should not place undue reliance on our forward-looking statements.
These forward-looking statements are based on information, plans and estimates at the date of this communication. The Company
undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors,
new information, future events or other changes.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits. The following exhibit is being furnished herewith this Current Report on Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ALERE INC. |
|
|
|
|
|
Date: May 22, 2017
|
By:
|
/s/ James Hinrichs |
|
|
|
James Hinrichs
|
|
|
|
Executive Vice President and Chief Financial Officer
|
|
|
|
|